RxDoctor Payments Data

Nilesh Baxi, MD

Psychiatry · Mountain Top, PANPI 1851322457

Payments from drug & device makers

$4,384in general payments, 2019–2025

Across 186 payments — averaging $23.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Teva Pharmaceuticals USA, Inc.$929
  • Alkermes, Inc.$588
  • Neurocrine Biosciences, Inc.$528
  • Otsuka America Pharmaceutical, Inc.$404
  • AbbVie$170
  • plus $723 from 10 others

What the payments were for

  • Food & beverage$4,27998%
  • Education$1042%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,384 in reported general payments places this provider in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$116,966
Medicare patients
225
Services billed
1,321

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate42$147,633
Abilify MaintenaAripiprazole22$63,622
AristadaAripiprazole Lauroxil18$56,058
VraylarCariprazine Hcl16$24,811
Aripiprazole112$11,957
AbilifyAripiprazole11$6,127
Olanzapine174$3,552
Paliperidone ErPaliperidone12$3,076
Quetiapine Fumarate193$2,843
Clozapine31$1,677
Risperidone143$1,551
Trazodone Hcl131$1,479
Fluoxetine Hcl97$1,450
Fluphenazine Hcl19$1,174
Duloxetine Hcl106$1,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$1,043$147,63342 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$404$63,62222 claims
Alkermes, Inc.Aristada$588$56,05818 claims
AbbVieVraylar$170$24,81116 claims
E.r. Squibb & Sons, L.L.C.Abilify$101$6,12711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in Mountain Top

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →